Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Debt / NOTE 4.750% 5/0
-
Market price (% of par)
-
68.25%
-
Total 13F principal
-
$131,395,000
-
Principal change
-
+$131,395,000
-
Total reported market value
-
$91,099,000
-
Number of holders
-
17
-
Value change
-
+$91,098,820
-
Number of buys
-
17
Institutional Holders of PARATEK PHARMACEUTICALS INC - NOTE 4.750% 5/0 as of Q2 2019
As of 30 Jun 2019,
PARATEK PHARMACEUTICALS INC - NOTE 4.750% 5/0 was held by
17 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$131,395,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, UBS OCONNOR LLC, UBS Group AG, PenderFund Capital Management Ltd., CAPSTONE INVESTMENT ADVISORS, LLC, GEODE CAPITAL MANAGEMENT, LLC, GABELLI FUNDS LLC, PALISADE CAPITAL MANAGEMENT LLC/NJ, MACQUARIE GROUP LTD, and CNH PARTNERS LLC.
This page lists
17
institutional bondholders reporting positions
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.